BR112021017203A2 - Leucina, acetil leucina e análogos relacionados para o tratamento de doenças - Google Patents

Leucina, acetil leucina e análogos relacionados para o tratamento de doenças

Info

Publication number
BR112021017203A2
BR112021017203A2 BR112021017203A BR112021017203A BR112021017203A2 BR 112021017203 A2 BR112021017203 A2 BR 112021017203A2 BR 112021017203 A BR112021017203 A BR 112021017203A BR 112021017203 A BR112021017203 A BR 112021017203A BR 112021017203 A2 BR112021017203 A2 BR 112021017203A2
Authority
BR
Brazil
Prior art keywords
leucine
pharmaceutically acceptable
acceptable salt
acetyl
diseases
Prior art date
Application number
BR112021017203A
Other languages
English (en)
Portuguese (pt)
Inventor
Mallory Factor
Taylor Fields
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of BR112021017203A2 publication Critical patent/BR112021017203A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021017203A 2019-03-02 2020-03-02 Leucina, acetil leucina e análogos relacionados para o tratamento de doenças BR112021017203A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962812987P 2019-03-02 2019-03-02
US201962842296P 2019-05-02 2019-05-02
US201962888894P 2019-08-19 2019-08-19
US201962895144P 2019-09-03 2019-09-03
PCT/IB2020/051767 WO2020178721A1 (en) 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease

Publications (1)

Publication Number Publication Date
BR112021017203A2 true BR112021017203A2 (pt) 2021-12-14

Family

ID=69845470

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017203A BR112021017203A2 (pt) 2019-03-02 2020-03-02 Leucina, acetil leucina e análogos relacionados para o tratamento de doenças

Country Status (25)

Country Link
US (1) US20220142959A1 (https=)
EP (2) EP4464378A3 (https=)
JP (2) JP7555346B2 (https=)
KR (2) KR102941068B1 (https=)
CN (2) CN119097618A (https=)
AU (2) AU2020231189B2 (https=)
BR (1) BR112021017203A2 (https=)
CA (1) CA3131948A1 (https=)
DK (1) DK3934637T3 (https=)
ES (1) ES2990183T3 (https=)
FI (1) FI3934637T3 (https=)
HR (1) HRP20241150T1 (https=)
HU (1) HUE068527T2 (https=)
IL (2) IL285870B2 (https=)
LT (1) LT3934637T (https=)
MA (1) MA55199B1 (https=)
MD (1) MD3934637T2 (https=)
MX (2) MX2021010568A (https=)
PL (1) PL3934637T3 (https=)
PT (1) PT3934637T (https=)
RS (1) RS65849B1 (https=)
SG (1) SG11202109512SA (https=)
SI (1) SI3934637T1 (https=)
SM (1) SMT202400334T1 (https=)
WO (1) WO2020178721A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
JP7471298B2 (ja) * 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体
US20250025442A1 (en) * 2020-12-10 2025-01-23 Texas Tech University System BCAA-Lowering Compounds for Prevention and/or Treatment of Alzheimer's Disease and Related Disorders
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
WO2024243004A2 (en) * 2023-05-19 2024-11-28 The Children's Hospital Of Philadelphia Compositions and methods for treating traumatic brain injury
WO2025166100A1 (en) * 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders
WO2025264957A2 (en) * 2024-06-20 2025-12-26 Intrabio Inc. Acetyl leucine for treating neurodevelopmental disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
US20140080885A1 (en) * 2012-09-13 2014-03-20 University Of South Florida (A Florida Non-Profit Corporation) Methods of treating traumatic brain injury
US10905670B2 (en) * 2016-04-19 2021-02-02 Intrabio Ltd. Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
WO2018029658A1 (en) * 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
NZ750391A (en) 2016-08-11 2026-03-27 Intrabio Ltd Pharmaceutical compositions and uses directed to lysosomal storage disorders
WO2019036442A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF NEURONAL INJURY

Also Published As

Publication number Publication date
SG11202109512SA (en) 2021-09-29
ES2990183T3 (es) 2024-11-29
CN114040757A (zh) 2022-02-11
IL285870B2 (en) 2025-12-01
MA55199A (fr) 2022-01-12
SMT202400334T1 (it) 2024-09-16
IL321899A (en) 2025-09-01
CA3131948A1 (en) 2020-09-10
US20220142959A1 (en) 2022-05-12
IL285870B1 (en) 2025-08-01
EP3934637A1 (en) 2022-01-12
RS65849B1 (sr) 2024-09-30
LT3934637T (lt) 2024-08-26
JP2024170602A (ja) 2024-12-10
EP4464378A3 (en) 2025-04-09
MD3934637T2 (ro) 2024-12-31
KR102941068B1 (ko) 2026-03-18
JP2022522819A (ja) 2022-04-20
AU2020231189A1 (en) 2021-09-30
MX2024015063A (es) 2025-01-09
EP3934637B1 (en) 2024-07-31
PT3934637T (pt) 2024-08-30
JP7555346B2 (ja) 2024-09-24
MX2021010568A (es) 2021-11-12
HRP20241150T1 (hr) 2024-11-22
AU2025204995A1 (en) 2025-07-17
WO2020178721A1 (en) 2020-09-10
PL3934637T3 (pl) 2024-10-14
AU2020231189B2 (en) 2025-07-24
FI3934637T3 (fi) 2024-09-02
DK3934637T3 (da) 2024-09-02
CN119097618A (zh) 2024-12-10
KR20250171484A (ko) 2025-12-08
SI3934637T1 (sl) 2024-10-30
IL285870A (en) 2021-10-31
CN114040757B (zh) 2024-09-20
KR20210135272A (ko) 2021-11-12
MA55199B1 (fr) 2024-08-30
HUE068527T2 (hu) 2025-01-28
EP4464378A2 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
BR112021017203A2 (pt) Leucina, acetil leucina e análogos relacionados para o tratamento de doenças
BR112022000231A2 (pt) Novos métodos
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
BR112021026334A2 (pt) Macrófagos ativados por hdac6, composições, e usos dos mesmos
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
WO2016090024A3 (en) Combination therapy for treatment of cancer
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
TW201625286A (zh) 靈芝免疫調節蛋白於促進神經突生長之新用途
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
RU2016102092A (ru) Тауроурсодезоксихолевая кислота (tudca) для применения в лечении нейродегенеративных нарушений
BR112015012497A2 (pt) combinações farmacêuticas
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
EP4069251A4 (en) SALTS AND POLYMORPHS OF CETHROMYCIN FOR THE TREATMENT OF DISEASES
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
BR112019023817A8 (pt) Composições tópicas e métodos para o tratamento de doenças da pele
BR112022012226A2 (pt) Métodos, método para preparar uma forma cristalina, forma cristalina, compostos e sal
BR112022004847A2 (pt) Método para tratar uma doença ou distúrbio de neurodesenvolvimento

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]